Nicox and Immco to develop Sjögren's syndrome diagnostic device

Article

Nicox has joined forces with Immco Diagnostics to offer tests for the early detection of Sjögren's syndrome.

Nicox has joined forces with Immco Diagnostics to offer tests for the early detection of Sjögren's syndrome.

The collaboration aims to give eye care practitioners and patients increased access to the test that offers potentially more efficient management of the chronic disease.

Undiagnosed Sjögren's syndrome could be discovered in as many as 1 in 10 dry eye patients and could lead to other disorders of the exocrine glands and an increased risk of lymphoma.

The new test, developed by researchers at the University at Buffalo, New York, USA, combines novel and traditional markers that support an accurate and early diagnosis with high sensitivity and specificity.

Nicox Inc Executive Vice President and General Manager, Mr Jerry St Peter, commented, “Immco is a well-established and innovative organization with a reputation for cutting edge science and high quality products. The addition of this new test into our portfolio synergizes well with our existing point-of-care offering, and will contribute to the momentum we are building in the marketplace with AdenoPlus.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.